Back to results
US 11,236,141 B2Granted
Targeted mutant interferon-beta and uses thereof
AssigneesOrionis Biosciences BV, Vib Vzw, Universiteit Gent
InventorsNikolai Kley, Jan Tavernier, Frank Peelman
Life of this patent
Estimating the term…
Abstract
The present invention relates, in part, to chimeric proteins comprising mutant interferon-β and their use as therapeutic agents.
Claims16
A chimeric protein comprising:
- (a) a modified IFN-β, said modified IFN-β having one or more mutations that confer reduced affinity and/or reduced activity for or at interferon-α/β receptor (IFNAR) as compared to a wild type IFN-β, and
- (b) one or more targeting moieties, said targeting moieties comprising recognition domains which specifically bind to antigens or receptors of interest, wherein:
- the modified IFN-β and the one or more targeting moieties are optionally connected with one or more linkers,
- the modified IFN-β comprises:
- (i) Y92G, I95A, and N96G mutations,
- (ii) K123G and R124G mutations,
- (iii) F67G, L88G, and Y92G mutations, or
- (iv) F67S, L88S, and Y92S mutations, and
- the recognition domain is a single-domain antibody or a single-chain antibody (scFv).
6 more elements
A chimeric protein comprising:
- (a) a modified IFN-β, said modified IFN-β having one or more mutations that confer reduced affinity and/or reduced activity for or at interferon-α/β receptor (IFNAR) as compared to a wild type IFN-β, and
- (b) one or more targeting moieties, said targeting moieties comprising recognition domains which specifically bind to antigens or receptors of interest, wherein:
- the modified IFN-β and the one or more targeting moieties are optionally connected with one or more linkers,
- the modified IFN-β comprises:
- (i) W22G and R27G mutations,
- (ii) L32A and R35A mutations,
- (iii) L151G and R152A mutations, or
- (iv) V148G and R152A mutations, and
- the recognition domain is a single:
- domain antibody or a single-chain antibody (scFv).
7 more elements
Dependencies are inferred from the claim text.